Kornimate/medical-research-clean huggingface dataset:
enhanced external counterpulsation

Conditions: Coronary Artery Disease; Congestive Heart Failure

Summary: enhanced external counterpulsation (eecp) is a noninvasive circulatory assist device that has been as a treatment option for refractory angina in left ventricular (lv) dysfunction. recently, its potential role in heart failure management has been shown. however, although the concept of eecp was introduced almost four decades ago, and despite growing evidence supporting the clinical benefit and safety of this therapeutic modality, little is firmly established regarding the mechanisms responsible for the benefit of eecp include improvement in endothelial function, promotion of coronary collateralization, enhancement of ventricular function, and peripheral effects. therefore, the major aim of this study is to provide an alternative treatment, eecp, for those unsuitable for standard procedures, especially for patients whose heart failure was caused by repeated myocardial infarction, called ischemic cardiomyopathy (icmp), and to evaluate the clinical outcome and the endothelial function before and after 35 hours of eecp treatment.


Eligibility criteria:
inclusion criteria: * the inclusion criteria is left ventricular ejection fraction (lvef) less than 40% by means of left ventricular angiography and symptomatic mild-to-moderate heart failure (new york heart association \[nyha\] functional class ii-iii). the patient was included if there is no suitable target for either percutaneous coronary intervention or surgical bypass grafting. exclusion criteria: * if he/she has moderate or severe aortic regurgitation (ar), history of deep vein thrombosis, or significant arrhythmia.

Keywords: eecp ischemic cardiomyopathy endothelin-1 ischemia coronary artery diseases congestive heart failure not amenable to standard procedures
phase i/ii, open label, randomized, safety and immunogenicity following dtwp-hepatitis b-hib-ipv vaccine (bio farma) in indonesian infants

Conditions: Vaccine Adverse Reaction; Vaccine Reaction

Summary: this trial is open label, comparative, randomized, phase i/ii study, experimental, randomized, open-label, three arm parallel group study. the primary objective for phase i is to evaluate the safety of the dtwp-hepatitis b-hib-ipv (bio farma) vaccine within 7 days after each dose. the primary objective for phase ii is to evaluate protectivity of dtwp-hepatitis b-hib-ipv (bio farma) vaccine.

this trial is open label, comparative, randomized, phase i/ii study. for phase i, approximately 75 subjects will be recruited and will seamlessly continue to phase ii recruiting 390 subject, in total 465 subjects. in this study, dtwp-hepatitis b-hib-ipv (bio farma) vaccine will be compared to an active control (registered dtwp-hepatitis b-hib vaccine and registered inactivated polio vaccine). there are 2 formulas of dtwp-hepatitis b-hib-ipv vaccine which will be used in the study. the regimen of the vaccine is 0,5 ml injected three-dose regimen with 28 days interval between doses. on the other hand, the control group will receive 0,5 ml of registered dtwp-hepatitis b-hib vaccine and 0,5 ml inactivated bio farma vaccine injected in three-dose regimen with 28 days interval between doses. the safety and immunogenicity result of the phase i study will determine the continuation of the next phase clinical trial. clinical trial of phase ii can be conducted after safety observation within 28 days after the third dose in phase i. three hundred and ninety (390) healthy subjects aged 6-11 weeks of age will be recruited in phase ii trial.

Eligibility criteria:
inclusion criteria: 1. infant 6-11 weeks of age. 2. infant born after 37-42 weeks of pregnancy. 3. infant weighing more than 2.5 kg at birth. 4. father or mother, or legally acceptable representative properly informed about the study and signed the informed consent form. 5. parents will commit themselves to comply with the indications of the investigators and with the schedule of the trial. exclusion criteria: 1. child concomitantly enrolled or scheduled to be enrolled in another trial. 2. evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥37.5°c on day 0). 3. known history of allergy to any component of the vaccines. 4. history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. 5. known history of congenital or acquired immunodeficiency (including hiv infection). 6. child who has received in the previous 4 weeks of a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks). 7. other vaccination within the 7 days prior to inclusion with the exception of bcg and poliomyelitis. 8. any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. 9. infant with a known history of diphtheria, tetanus, pertussis, hib, hepatitis b infection.
the study of inflammation on blood glucose levels in obese people

Conditions: Obesity

Summary: chronic subaccute inflammation may underlie the development of diabetes cardiovascular disease and other components of the metabolic syndrome. rodent studies suggest diet induced obesity is associated with activation of the ikk/nf-kb pathway and this pathway can be inhibited by salicylates. this study seeks to determine the effect of salicylates in overweight persons.


Eligibility criteria:
inclusion criteria: * obesity (\> 85th% for age,bmi \> 30); hba1c \<6%; hemoglobin and/or hematocrit within 2 standard deviations of normal range, without high risk of bleeding, without donation of blood in the previous 2 months; without involvement in any study evaluating an investigational drug or device for the previous 2 months; normal clotting studies; if female using barrier or oral contraception and with a negative pregnancy test. exclusion criteria: * pregnant or lactating women; patients with abnormal liver function defined as elevation of bilirubin, alkaline phosphatase, alt, ast, or ggtp more than 1.5 times the upper limit of normal; patients with kidney disease (serum creatinine \> 1.5 mg/dl) macroalbuminuria (1+ protein on a standard urine dip-stick, or \> 300 mg urinary albumin/day); (patients with microalbuminuria will be enrolled); patients with any significant diseases or conditions, including emotional or psychiatric disorders and substance abuse, including history of binge drinking, that, in the opinion of the investigator, are likely to alter the patient's ability to complete the study ; patients with metabolic acidosis (abnormal anion gap); history of gastric ulcer, dyspepsia, or upper or lower gi bleed; history of allergy to aspirin, or bleeding diathesis or currently on oral anticoagulants including warfarin, heparin, aspirin or other nsaids; patients with major vascular event within 6 months of screening for the study (e.g., mi, stroke, cabg, angioplasty, pv surgery); patients with chronic heart disease, or a history of myocardial infarction or stroke. symptomatic angina pectoris or cardiac insufficiency as defined by the nyha; classification as functional class iii or iv; patients who smoke more than one pack of cigarettes daily; patients taking treatment medications known to affect insulin sensitivity (e.g. diuretics, beta-blockers); patients with inadequately controlled serum lipid levels (total cholesterol ≥ 275 mg/dl and fasting triglycerides ≥ 450 mg/dl); patients with history of cancer within 5 years prior to screening for the study other than basal cell carcinoma; active alcohol or other substance abuse.

Keywords: obesity metabolic syndrome diabetes inflammation
the national musculoskeletal audit and research database

Conditions: Musculoskeletal Diseases

Summary: developing and testing a musculoskeletal national audit in community/primary care

this project aims to develop, setup and test an msk national audit which will use patient and clinician inputted data to measure the quality of care for patients presenting in community msk services and general practice with common msk conditions. secondly this project aims to use the national msk audit information to understand and improve the quality and consistency of care for msk patients.

Eligibility criteria:
inclusion criteria: (msk services) * msk service seeing adult (+18 years) set in community care * msk service with at least 10 wte hcps * system in place for digital collection of prom/prem data (fcp services) * fcp service seeing adult (+18 years) in primary care * fcp service with at least 1 wte fcp seeing msk patients * use of emis or systmone * able to implement midlands fcp template * system in place for digital collection of prom/prem data (for patients) * +18 years * active phone number or verified email address to participate in the patient questionnaire * able to provide informed consent exclusion criteria: (msk services) \* secondary care msk services (for patients) * has declined for data to be part of research as part of consent process * unable to complete surveys due to health issues including severe or terminal illness, severe learning difficulties or psychological disorders

Keywords: primary care community benchmarking audit quality improvement
a study of morab-202 in participants with previously treated metastatic non-small cell lung cancer (nsclc) adenocarcinoma (ac)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the aim of this study is to characterize the safety and tolerability of morab-202, and to assess the objective response rate in participants with previously treated, metastatic nsclc ac.


Eligibility criteria:
inclusion criteria: * histologically or cytologically documented metastatic nsclc ac (as defined by the 8th international association for the study of lung cancer classification). * measurable target disease assessed by the investigator according to recist 1.1. * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 exclusion criteria: * nsclc histologies other than ac (ie, squamous cell carcinoma, large cell carcinoma). * significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage. * prior pneumonectomy. prior lobectomy and segmentectomy are allowed \> 12 months before treatment. * recent chest radiotherapy. participants with chest or chest wall radiation may be permitted if chest radiation is documented \> 6 months before starting study treatment. other protocol-defined inclusion/exclusion criteria apply.

Keywords: nsclc morab-202 farletuzumab ecteribulin adenocarcinoma
finnish imaging of shoulder study

Conditions: Shoulder Pain; Rotator Cuff Tears; Glenoid Labrum Tear; Osteo Arthritis Shoulders

Summary: in the finnish imaging of shoulder study we will recruit 600 participants from a nationally representative general population sample. participants aged 40 to 75 years will be invited to a clinical visit that includes assessment of general health, shoulder history and symptoms, and bilateral clinical examination and shoulder imaging (both plain radiography and mri). we aim to assess the prevalence of abnormal imaging findings in both asymptomatic and symptomatic individuals and explore possible risk factors for abnormal imaging findings and shoulder symptoms.


Eligibility criteria:
inclusion criteria: * ambulatory * participation in the health 2000 survey * informed consent exclusion criteria: * dementia * terminal cancer * previous shoulder joint replacement * contraindications for mri

Keywords: prevalence imaging shoulder clinical examination asymptomatic general population shoulder function
parents of young adults with type 1 diabetes: an exploratory study

Conditions: Type1diabetes; Parents

Summary: the purpose of this mixed-methods study is to explore the lived experience of parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence, and to test the preliminary efficacy of a mobile education program to reduce parental distress.

as young adults with t1d navigate the transition process to independence, they often do so in partnership with their parents, who are tasked with providing support and guidance. at this time, however, no structured education program exists for these parents. in addition, little is known about their learning needs, levels of distress, and readiness to provide appropriate guidance for their emerging adult children. this represents a gap in the literature and an opportunity to undertake exploratory research to learn more about this population so that meaningful education and support can be provided. aim 1. to describe the lived experience and diabetes-specific educational needs of parents of young adults with type 1 diabetes who are transitioning to independence. aim 2. to measure the effect of a mobile diabetes education program on diabetes distress levels of parents of young adults ages 18 to 25 years who are transitioning to independence.

Eligibility criteria:
inclusion criteria: * (1) ability to read and speak english * (2) parent of a child aged ≥18 years and ≤25 years with a diagnosis with t1d * (3) must have access to a smartphone or tablet or laptop/desktop computer with internet access. exclusion criteria: * (1) significant medical comorbidity in the participant that could, in the opinion of the pi, affect participant's capacity to complete study follow up; * (2) inability to read and speak english.

Keywords: mhealth
retrograde intrarenal surgery (rirs) with suction

Conditions: Renal Stone

Summary: suction has been initially used in endoscopic stone management for more than 25 years during pcnl, but the emergence of new devices applying suction through patented ureteroscopes, ureteral access sheaths (uas) and ureteral catheters led to application of suction in urs/rirs. the application of ureteral access sheath (uas) in rirs can improve surgical vision , reduce intrarenal pressure (irp) ,and decrease postoperative infectious complications .


Eligibility criteria:
inclusion criteria: * single stone * medium sized stone ≤ 3 cm * renal stone * age group \> 18 exclusion criteria: * multiple renal stones * stone size \> 3 cm * age group \< 18 * solitary kidney * obstruction distal to the stone. * urinary tract infection
neuromodulatary efficacy of transcranial direct current stimulation in severe refractory primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: primary dysmenorrhea (pdm), defined as menstrual pain without discernable organic causes, is inexorably common in adolescent women, about 40-90% of women may suffer from it, and 20% of them can be severe in the context of being refractory to medication, daily function impairment, and having pain of severe degree. novel therapeutic method is in need for pain alleviation for this particular phenotype. it has been reported that pdm females may engage motor-cortex based descending pain modulation system in our resting-state functional magnetic resonance imaging (rs-fmri) and thermal pain-activation fmri studies. based on the reported analgesic efficacy of transcranial direct current stimulation (tdcs) on the motor cortex for various experimental painful conditions and clinical pain disorders, it is plausible that tdcs can be effective for the severe and medication-refractory pdm patients. this study aim to investigate the analgesic efficacy of tdcs in severe pdms and to elucidate the dynamic brain neuroplasticity in the context of experimental pain after tdcs intervention. thirty severe pdms will be recruited and randomly allocated to either real or sham group in a triple-blind manner. experimental pain electrical stimulation will be performed before and after the tdcs intervention. the experimental pain-evoked magnetoencephamographic (meg) data will be correlated with behavioral and psychological measurements. this is the first study in the literature investigating the tdcs efficacy for acute pain in severe pdm. the result can promise a new possibility for clinical application.


Eligibility criteria:
inclusion criteria: * 20-35 years old pdm patients * right-handedness * a regular menstrual cycle: 27-32 days * cramping pain during the menstrual period in the last 6 months , vas ≧ 7 * abstinence for daily activities due to pdm * need analgesic or physical therapy despite of no prominent effect exclusion criteria: * history of head injury * pathological pituitary gland disease * organic pelvic disease, psychiatric disorder * pregnancy, childbirth * a metal or pacemaker implant. * take hormone agents within 6 months

Keywords: dysmenorrhea neuromodulation transcranial direct current stimulation neuroplasticity neuroimaging
anti emetic efficacy of combination of ramosetron and premixture of naloxone with patient-controlled analgesia

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is one of the most undesirable complications after general anesthesia, and may lead to increased hospital stay and health care costs. the risk factors for ponv include sex (female population), nonsmoking status, past history of motion sickness and/or previous ponv, duration of anesthesia and surgical type (particular gynecologic surgery) and postoperative use of opioids. the overall incidence of ponv has been reported to be 30% with considerable variability, but can increase up to 69%- 80% in women undergoing gynecologic surgery with general anesthesia and morphine-patient controlled analgesia (pca). serotonin receptor antagonists (5-ht3) have been suggested one of the first line therapies for preventing ponv because of their efficacy and few side effects compared with other antiemetics. however, despite the use of this treatment, the incidence of ponv has been reported to be between 48 % and 50%. naloxone is a drug used to counter the effects of opioid. it was found that administration of low dose naloxone prevents opioid side effects such as nausea and pruritus without affecting analgesia or opioid requirements in patient receiving morphine pca. it was reported that the use of two antiemetic acting at different mechanisms is better to prevent ponv than monotherapy. therefore, this prospective, randomized, controlled study was designed to investigate the antiemetic efficacy of combination of ramosetron and premixture of naloxone with morphine pca after gynecologic surgery.


Eligibility criteria:
inclusion criteria: * nonsmoking women (asa physical status of i or ii) scheduled for gynecologic surgery under general anesthesia and postoperative analgesia with a pca device were included exclusion criteria: * known hypersensitivity to study medication; the use of antiemetics within 24 hours before surgery; the presence of gastrointestinal, renal, hepatic, or psychiatric disease.

Keywords: ponv ramosetron naloxone
treating amyotrophic lateral sclerosis (als) with r(+) pramipexole dihydrochloride monohydrate at 60 mg/day

Conditions: Amyotrophic Lateral Sclerosis

Summary: r(+) pramipexole dihydrochloride monohydrate \[r(+)ppx\], an experimental neuroprotective drug, is provided in this open label extension study to als patients who have participated in earlier clinical protocols.


Eligibility criteria:
inclusion criteria: * definite diagnosis of als exclusion criteria: * no prior participation in r(+)ppx clinical studies
effects of anesthesia type on inflammatory response

Conditions: Spinal Aneshtesia; General Anesthetic; Inflammation; Neutrophils; Total Knee Arthroplasty; White Blood Cells

Summary: in total knee arthroplasty, surgical and anesthetic procedures can lead to a significant increase in systemic inflammation. this procedure is frequently performed under either general or spinal anesthesia. however, studies investigating the effect of anesthesia type on systemic inflammation have shown conflicting results. the systemic inflammatory response index (siri) and the systemic immune-inflammation index (sii) provide important information about the extent of systemic inflammation. this study aimed to investigate the effects of general and spinal anesthesia on perioperative changes in sii and siri during total knee arthroplasty. between january 2020 and april 2025, data from 849 patients who underwent total knee arthroplasty were retrospectively reviewed. patients received either spinal anesthesia (group s) or general anesthesia (group g). the groups were compared in terms of changes in perioperative sii and siri (δsii and δsiri), total opioid consumption, postoperative complications, and length of hospital stay.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 75 years * patients with asa physical status i or ii * patients who have underwent total knee arthroplasty under general or spinal anesthesia exclusion criteria: * patients with bmi ≥40 kg/m2 * patients with asa physical status ≥iii * patients with severe cardiopulmonary or metabolic disorders, coagulation disorders or active infection * patients with known allergies or chronic steroid use * patients with incomplete laboratory data * patients who underwent revision total knee arthroplasty * patients who required intraoperative conversion from spinal to general anesthesia * patients with a history of major trauma and/or emergency surgery
vilazodone for corticosteroid-induced memory impairment

Conditions: Memory Impairment

Summary: the purpose of this study is to examine whether vilazodone attenuates the memory and mood effects of corticosteroids on the human hippocampus in 24 healthy controls.

in animals and humans, stress and corticosteroid excess are associated with changes in hippocampal structure and functioning. these findings have important implications to the millions of patients taking prescription corticosteroids and to patients with major depressive disorder or bipolar disorder who have elevated cortisol levels and memory impairment. the investigators believe that vilazodone may be a medication that can block the effects of hydrocortisone on the human hippocampus. the investigators propose to examine whether vilazodone attenuates the effects of corticosteroids in a randomized, double-blind, placebo-controlled pilot study using a within-subject crossover design.

Eligibility criteria:
inclusion criteria: * healthy men and women age 18-50 years * education of ≥ 12 years and baseline ravlt total words recalled score ≥ 35 (normal baseline memory) * bmi between 18.5-30 (not underweight or obese) exclusion criteria: * history of major psychiatric illness defined as major depressive disorder, bipolar disorder, posttraumatic stress disorder, panic disorder, schizoaffective disorder, schizophrenia, eating disorders, or drug/alcohol abuse/dependence or current tobacco use * history of neurological disorders including seizures, brain surgery, multiple sclerosis, parkinson's disease * taking cns-acting medications within 30 days of study * history of allergic reaction or medical contraindication to vilazodone or hydrocortisone * significant medical conditions (e.g., myocardial infarction, cancer, diabetes) * vulnerable population including pregnant or nursing women, the incarcerated, and severe cognitive disorders * baseline hrsd (hamilton rating scale for depression) \> 7 or current suicidal ideation or history of suicide attempt * history of systemic corticosteroid (cs) use or recent (past 6 months) inhaled cs use
trial of a novel fibrinolytic (alfimeprase) to clear thrombosed vascular access devices

Conditions: Catheters, Indwelling

Summary: this trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). the trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.


Eligibility criteria:
subjects must: * have a dysfunctional central venous access device (cvad) defined as unable to withdraw 3 ml blood * have had the device in place for \> 48 hours * be clinically stable * be 18 or older * give informed consent

Keywords: central venous access device thrombosis central venous catheter thrombolysis fibrinolysis